文献速递糖尿病

二甲双胍失效的预测因素:利用电子健康记录数据识别高风险患者

Predictors of Metformin Failure: Repurposing Electronic Health Record Data to Identify High-Risk Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究在亚利桑那、密西西比和明尼苏达三个中心纳入22 047例起始二甲双胍治疗的患者,定义失效为18个月内未达HbA1c<7%或启动双药治疗,观察到失效率43%。包含基线HbA1c、年龄、性别和种族的XGBoost模型区分度C指数为0.731(95%CI 0.722, 0.740),加入其他临床因素后提升至0.745(95%CI 0.737, 0.754,P<.0001),基线HbA1c是最强预测因素。

要点

  • 22 047例起始二甲双胍患者中失效率为43%,基线HbA1c是最强预测因素。
  • 仅用基线HbA1c、年龄、性别和种族的模型C指数为0.731(95%CI 0.722, 0.740)。
  • 加入其他临床因素后模型C指数提升至0.745(95%CI 0.737, 0.754,P<.0001)。

核心结论

  • 基线HbA1c是二甲双胍失效的最强预测因素,加入其他因素可显著提升模型性能,常规临床数据或可用于识别二甲双胍失效高风险患者,这些患者可能从更密切监测和更早治疗强化中获益。

研究设计与样本

  • 在亚利桑那、密西西比和明尼苏达三个中心识别至少一次糖尿病筛查异常且起始二甲双胍治疗的患者队列。
  • 共纳入22 047例二甲双胍起始者(48%女性,平均年龄57±14岁),包括2141例非洲裔美国人、440例亚洲人、962例其他/多种族、1539例西班牙裔和16 764例非西班牙裔白人。
  • 二甲双胍失效定义为起始后18个月内未达目标糖化血红蛋白(HbA1c)<7%或启动双药治疗。
  • 使用基于树的极端梯度提升(XGBoost)模型评估整体风险预测性能及个体因素的相对贡献。

主要发现

  • 在该大型多样化人群中观察到二甲双胍失效率为43%。
  • 包含基线HbA1c、年龄、性别和种族的XGBoost模型对二甲双胍失效风险具有高区分度,C指数为0.731(95%CI 0.722, 0.740)。
  • 基线HbA1c对应最大的特征性能,较高水平与二甲双胍失效相关。
  • 加入其他临床因素后模型性能提升至0.745(95%CI 0.737, 0.754,P<.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metformin is the first-line drug for treating diabetes but has a high failure rate. OBJECTIVE: To identify demographic and clinical factors available in the electronic health record (EHR) that predict metformin failure. METHODS: A cohort of patients with at least 1 abnormal diabetes screening test that initiated metformin was identified at 3 sites (Arizona, Mississippi, and Minnesota). We identified 22 047 metformin initiators (48% female, mean age of 57 ± 14 years) including 2141 African Americans, 440 Asians, 962 Other/Multiracial, 1539 Hispanics, and 16 764 non-Hispanic White people. We defined metformin failure as either the lack of a target glycated hemoglobin (HbA1c) (<7%) within 18 months of index or the start of dual therapy. We used tree-based extreme gradient boosting (XGBoost) models to assess overall risk prediction performance and relative contribution of individual factors when using EHR data for risk of metformin failure. RESULTS: In this large diverse population, we observed a high rate of metformin failure (43%). The XGBoost model that included baseline HbA1c, age, sex, and race/ethnicity corresponded to high discrimination performance (C-index of 0.731; 95% CI 0.722, 0.740) for risk of metformin failure. Baseline HbA1c corresponded to the largest feature performance with higher levels associated with metformin failure. The addition of other clinical factors improved model performance (0.745; 95% CI 0.737, 0.754, P < .0001). CONCLUSION: Baseline HbA1c was the strongest predictor of metformin failure and additional factors substantially improved performance suggesting that routinely available clinical data could be used to identify patients at high risk of metformin failure who might benefit from closer monitoring and earlier treatment intensification.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bielinski SJ, Yanes Cardozo LL, Takahashi PY, et al. Predictors of Metformin Failure: Repurposing Electronic Health Record Data to Identify High-Risk Patients. J Clin Endocrinol Metab. 2023. PMID: 36617249. doi:10.1210/clinem/dgac759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。